DWP14012
Phase 3Small molecule
Daewoong Pharmaceutical Co. LTD.DWP14012 is one of 102 small molecule programs targeting Chronic Gastritis. It is currently in Phase 3.
4
Indications
26
Total Trials
0
Active Trials
101
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
80 competitors in Gastroesophageal Reflux Disease
#DrugCompanyPhaseTrials
1Prevacid
TakedaPhase 3
Norpramin
VValidus Pharmaceuticals
Approved
Rabeprazole ER
EisaiPhase 3
Zantac 150
CChattem
Phase 3
Pulmicort
SSalix
Phase 3
Esomeprazole Mg
AstraZenecaPhase 3
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Domperidone
Johnson & JohnsonPhase 3
Lioresal
NovartisPhase 2
Nexium
YYooyoung Pharmaceutical Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Tics5 trials
Gastroesophageal Reflux Disease3 trials
Interaction2 trials
Drug Interactions2 trials
8 more indications
Efficacy and Safety2 trials
Esophagitis2 trials
Oral2 trials
Treatment2 trials
Peptic ulcer1 trial
Chronic Gastritis1 trial
Clinical Trial1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DWP14012. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details